Bioanalysis by LC-MS/MS and preclinical pharmacokinetic interaction study of ribociclib and oleanolic acid

26 Oct 2022

Journal articles MS (LC–MS/MS, HRMS, IMS)

Sahu A, Jadav T, Rajput N, Sharma M N & Sengupta P | Bioanalysis, 14(15), 1051-1065, (2022) Keywords: bioanalytical method • oleanolic acid • pharmacokinetic interaction • ribociclib Background: Ribociclib (RIBO), approved in 2017 for HR-positive and HER-2-negative metastatic breast cancer treatment is reported to have the potential to induce hepatobiliary toxicity in patients. Oleanolic acid (OLA) has hepatoprotective potential that can be beneficial if coadministered with RIBO. Methodology & results: The primary scope of this study was to develop quantitative bioanalytical methods for RIBO and OLA. Two methods (for +ve electrospray ionization [ESI] and -ve ESI) were developed and validated according to USFDA bioanalytical guidelines. Discussion/conclusion:...